Nav: Home

UW team finds key to common cancer pathway

March 18, 2019

MADISON, Wis. -- Scientists have long known that the protein p53, when mutated, is a critical factor in the onset of many different kinds of cancer. In its unmutated form, however, it is known to protect against cancer.

These dueling qualities make the p53 protein and the gene that makes it among the most studied in biology, yet the molecular mechanisms that govern its stability and function have yet to be fully understood.

Writing this week (March 18, 2019) in the journal Nature Cell Biology, a team led by University of Wisconsin-Madison cancer researchers Richard A. Anderson and Vincent Cryns reports the discovery of an unexpected regulator of the critical protein, opening the door to the development of drugs that could target it.

"p53, like Janus, has two faces," says Anderson, referencing the Roman god of gates and doorways. "The p53 gene is the most frequently mutated gene in cancers, and when mutated it switches its function from a tumor suppressor to an oncogene that drives the majority of cancers."

Typically, explains Anderson of the UW School of Medicine and Public Health, the p53 protein serves as "the guardian of the genome," initiating the repair of DNA damaged by ultraviolet radiation, chemicals or other means and preventing tumor growth. When mutated, however, the protein goes rogue, becoming more stable and abundant than its unmutated counterpart, accumulating in the nucleus of the cell and causing cancer.

The research team, which includes study lead authors and postdoctoral fellows Suyong Choi and Mo Chen, found a new mechanism that drives this stability. The culprit: an enzyme called PIPK1-alpha and its lipid messenger, known as PIP2, which seem to behave as master regulators of p53.

The Wisconsin team showed that when a cell is stressed, whether by DNA damage or other means, the enzyme associates with p53 and produces PIP2, which binds strongly to it and promotes interaction between p53 and molecules known as small heat shock proteins. This stabilizes the protein complex, setting the stage for cancer, including aggressive cancers such as triple negative breast cancer.

"Small heat shock proteins are really good at stabilizing proteins," says Cryns, a professor of medicine in the UW School of Medicine and Public Health and expert on heat shock proteins. "In our case, their binding to mutant p53 likely facilitates its cancer-promoting actions, something we are actively exploring."

In the new study, the researchers also showed that when the PIP2 enzyme pathway is disrupted, mutant p53 does not accumulate and cause damage.

"If you can eliminate mutant p53, you might be able to eliminate cancers driven by p53," says Anderson.

The researchers are now actively searching for inhibitors of the PIPK1-alpha enzyme, a kinase, that could be used to treat tumors harboring p53 mutations.

"Although p53 is one of the most commonly mutated genes in cancer, we still do not have any drugs that specifically target p53," Cryns notes. "Our discovery of this new molecular complex points to several different ways to target p53 for destruction, including blocking the kinase or other molecules that bind to p53."

The findings, Anderson adds, were a little puzzling because the catalytic enzyme and PIP2 are typically and most abundantly found in cell membranes and not in the cell nucleus interior, where mutant p53 does its damage.

"This lipid pathway is weird," he says. "Lipids are supposed to be in membranes and this is not in a membrane compartment."
-end-
--Terry Devitt, (608) 262-8282, trdevitt@wisc.edu

This work was supported in part by a National Institutes of Health grant GM114386 (R.A.A.), Department of Defense Breast Cancer Research Program grants W81XWH-17-1-0258 (R.A.A.) and W81XWH-17-1-0259 (V.L.C.) and a grant from the Breast Cancer Research Foundation (V.L.C.).

DOWNLOAD IMAGE: https://uwmadison.box.com/v/cancer-pathway

CONTACT: Richard Anderson, (608) 262-3753, raanders@wisc.edu; Vincent Cryns, (608) 262-4786, vlcryns@medicine.wisc.edu

University of Wisconsin-Madison

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".